Two Sisters with Colchicine-Resistant form of Familial Mediterranean Fever on the Canakinumab Therapy: Clinical Case
Background. Colchicine-resistant cases of familial Mediterranean fever (FMF) are associated with high risk of kidney amyloidosis and severe episodes of the disease with pyretic fever, arthritis, pleurisies, pericarditis. It is difficult to achieve disease control in colchicine-resistant patients and...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
"Paediatrician" Publishers LLC
2020-01-01
|
| Series: | Вопросы современной педиатрии |
| Subjects: | |
| Online Access: | https://vsp.spr-journal.ru/jour/article/view/2234 |
| _version_ | 1797702230309076992 |
|---|---|
| author | Elena A. Ligostaeva Nadezhda A. Tsurikova Irina A. Tsiganok Nataliya N. Kobzeva Vadim Yu. Avdeenko |
| author_facet | Elena A. Ligostaeva Nadezhda A. Tsurikova Irina A. Tsiganok Nataliya N. Kobzeva Vadim Yu. Avdeenko |
| author_sort | Elena A. Ligostaeva |
| collection | DOAJ |
| description | Background. Colchicine-resistant cases of familial Mediterranean fever (FMF) are associated with high risk of kidney amyloidosis and severe episodes of the disease with pyretic fever, arthritis, pleurisies, pericarditis. It is difficult to achieve disease control in colchicine-resistant patients and it is required to use genetically engineered biologic drugs.Clinical Case Description. The observation of the family with severe course of FFL is presented. The successful use of canakinumab (monoclonal antibody to interleukin-1) in sisters with colchicine-resistant form of disease is described. Fever, articular and abdominal syndromes were completely reversed after 4 weeks of treatment as well as normalisation of laboratory tests was noted. Laboratory indexes of disease activity (erythrocyte sedimentation rate and C-reactive protein level) have stayed in reference ranges after 32 weeks of therapy, no new episodes of the disease were recorded. There were no adverse effect on the canakinumab therapy during the observation period (32 weeks).Conclusion. The high canakinumab efficacy in patients with severe colchicine-resistant forms of FMF is shown. |
| first_indexed | 2024-03-12T04:48:11Z |
| format | Article |
| id | doaj.art-a5ef08fc00d648debad1630c92726740 |
| institution | Directory Open Access Journal |
| issn | 1682-5527 1682-5535 |
| language | English |
| last_indexed | 2024-03-12T04:48:11Z |
| publishDate | 2020-01-01 |
| publisher | "Paediatrician" Publishers LLC |
| record_format | Article |
| series | Вопросы современной педиатрии |
| spelling | doaj.art-a5ef08fc00d648debad1630c927267402023-09-03T09:26:50Zeng"Paediatrician" Publishers LLCВопросы современной педиатрии1682-55271682-55352020-01-0118536236810.15690/vsp.v18i5.20601838Two Sisters with Colchicine-Resistant form of Familial Mediterranean Fever on the Canakinumab Therapy: Clinical CaseElena A. Ligostaeva0Nadezhda A. Tsurikova1Irina A. Tsiganok2Nataliya N. Kobzeva3Vadim Yu. Avdeenko4Областная детская клиническая больницаОбластная детская клиническая больницаОбластная детская клиническая больницаОбластная детская клиническая больницаОбластная детская клиническая больницаBackground. Colchicine-resistant cases of familial Mediterranean fever (FMF) are associated with high risk of kidney amyloidosis and severe episodes of the disease with pyretic fever, arthritis, pleurisies, pericarditis. It is difficult to achieve disease control in colchicine-resistant patients and it is required to use genetically engineered biologic drugs.Clinical Case Description. The observation of the family with severe course of FFL is presented. The successful use of canakinumab (monoclonal antibody to interleukin-1) in sisters with colchicine-resistant form of disease is described. Fever, articular and abdominal syndromes were completely reversed after 4 weeks of treatment as well as normalisation of laboratory tests was noted. Laboratory indexes of disease activity (erythrocyte sedimentation rate and C-reactive protein level) have stayed in reference ranges after 32 weeks of therapy, no new episodes of the disease were recorded. There were no adverse effect on the canakinumab therapy during the observation period (32 weeks).Conclusion. The high canakinumab efficacy in patients with severe colchicine-resistant forms of FMF is shown.https://vsp.spr-journal.ru/jour/article/view/2234детисемейная средиземноморская лихорадкаклинический случайпериодическая болезньколхицинканакинумабинтерлейкин 1активность болезнинежелательные реакции |
| spellingShingle | Elena A. Ligostaeva Nadezhda A. Tsurikova Irina A. Tsiganok Nataliya N. Kobzeva Vadim Yu. Avdeenko Two Sisters with Colchicine-Resistant form of Familial Mediterranean Fever on the Canakinumab Therapy: Clinical Case Вопросы современной педиатрии дети семейная средиземноморская лихорадка клинический случай периодическая болезнь колхицин канакинумаб интерлейкин 1 активность болезни нежелательные реакции |
| title | Two Sisters with Colchicine-Resistant form of Familial Mediterranean Fever on the Canakinumab Therapy: Clinical Case |
| title_full | Two Sisters with Colchicine-Resistant form of Familial Mediterranean Fever on the Canakinumab Therapy: Clinical Case |
| title_fullStr | Two Sisters with Colchicine-Resistant form of Familial Mediterranean Fever on the Canakinumab Therapy: Clinical Case |
| title_full_unstemmed | Two Sisters with Colchicine-Resistant form of Familial Mediterranean Fever on the Canakinumab Therapy: Clinical Case |
| title_short | Two Sisters with Colchicine-Resistant form of Familial Mediterranean Fever on the Canakinumab Therapy: Clinical Case |
| title_sort | two sisters with colchicine resistant form of familial mediterranean fever on the canakinumab therapy clinical case |
| topic | дети семейная средиземноморская лихорадка клинический случай периодическая болезнь колхицин канакинумаб интерлейкин 1 активность болезни нежелательные реакции |
| url | https://vsp.spr-journal.ru/jour/article/view/2234 |
| work_keys_str_mv | AT elenaaligostaeva twosisterswithcolchicineresistantformoffamilialmediterraneanfeveronthecanakinumabtherapyclinicalcase AT nadezhdaatsurikova twosisterswithcolchicineresistantformoffamilialmediterraneanfeveronthecanakinumabtherapyclinicalcase AT irinaatsiganok twosisterswithcolchicineresistantformoffamilialmediterraneanfeveronthecanakinumabtherapyclinicalcase AT nataliyankobzeva twosisterswithcolchicineresistantformoffamilialmediterraneanfeveronthecanakinumabtherapyclinicalcase AT vadimyuavdeenko twosisterswithcolchicineresistantformoffamilialmediterraneanfeveronthecanakinumabtherapyclinicalcase |